Alivus Life SciencesNSE:ALIVUS +3.31%84 Interest Coverage is 148.46 as of Mar. 2026, which is 24% below its 10-year median of 196.02. GuruFocus rates NSE:ALIVUS with a GF Score™ of 84/100 and a GF Value™ of ₹1,005.55 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 686 Drug Manufacturers companies, Alivus Life Sciences ranks better than 81.78% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Alivus Life Sciences's
Operating Income
for the
three
months ended in Mar. 2026 was ₹1,943 Mil. Alivus Life Sciences's Interest Expense for the
three
months ended in Mar. 2026 was ₹-13 Mil.
Alivus Life Sciences's interest coverage for the quarter that ended in Mar. 2026 was 148.46.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Alivus Life Sciences Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Alivus Life Sciences's Interest Coverage or its related term are showing as below:
NSE:ALIVUS'
s Interest Coverage Range Over the Past 10 Years
Min: 6.42 Med: 196.02 Max: 1098.28
Current: 134.39
NSE:ALIVUS's Interest Coverage is ranked better than 81.78% of 686
companies
in the Drug Manufacturers industry
Industry Median: 12.725
vs NSE:ALIVUS: 134.39
Alivus Life Sciences (NSE:ALIVUS) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Alivus Life Sciences Interest Coverage Related Terms
Alivus Life Sciences Interest Coverage Historical Data
* Premium members only.
The historical data trend for Alivus Life Sciences's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:ALIVUS vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alivus Life Sciences Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Alivus Life Sciences's Interest Coverage falls into.
Alivus Life Sciences Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alivus Life Sciences (NSE:ALIVUS) has a Interest Coverage of 148.46 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Alivus Life Sciences and its competitors. This is 24% below median its historical median of 196.02. Over the past decade, Alivus Life Sciences' Interest Coverage has ranged from 6.42 to 1,098.28. According to the industry distribution chart, Alivus Life Sciences ranks #125 out of 686 companies in the Drug Manufacturers industry, placing it in the top 18.2%.
Is Alivus Life Sciences' Interest Coverage too high?
Alivus Life Sciences' current Interest Coverage of 148.46 is 24% below median its 10-year median of 196.02. Over the past 10 years, this metric has ranged from a low of 6.42 to a high of 1,098.28. The Drug Manufacturers industry median Interest Coverage is 12.73. Alivus Life Sciences' value of 148.46 is 1066.7% above this industry median. Based on the distribution chart, Alivus Life Sciences ranks #125 out of 686 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alivus Life Sciences has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alivus Life Sciences ranks #125 out of 686 companies for Interest Coverage. This places Alivus Life Sciences in the top 18% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.73. Alivus Life Sciences' value of 148.46 is 1066.7% above this benchmark. Historically, Alivus Life Sciences' own Interest Coverage has ranged from 6.42 to 1,098.28 over the past decade. While the company's 10-year median is 196.02 vs. the industry median of 12.73, Alivus Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alivus Life Sciences's current Interest Coverage of 148.46 is 1066.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Alivus Life Sciences and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alivus Life Sciences's current Interest Coverage is 148.46, which is 24% below median its own 10-year median of 196.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,005.55, compared to a current price of ₹1,156.50 — trading 15% above its estimated fair value. The current Interest Coverage is 148.46, which is 24% below median its 10-year median of 196.02 and 1066.7% above the Drug Manufacturers industry median of 12.73. Alivus Life Sciences' overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current Interest Coverage is 148.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?
Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued.
The current stock price of ₹1,156.50 is trading 15% above its estimated GF Value™ of ₹1,005.55.
GuruFocus considers Alivus Life Sciences to be Modestly Overvalued.
Key valuation signals for NSE:ALIVUS:
Interest Coverage: 148.46 (24% below median its 10-year median of 196.02)
GF Value™: ₹1,005.55 vs. price of ₹1,156.50 (15% above fair value)
Industry Position: 1066.7% above the Drug Manufacturers median (#125 of 686)
No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
84GF Score
Get the complete analysis for NSE:ALIVUS
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALIVUS has been successfully added to your 
